[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1107531T1 - Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου - Google Patents

Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου

Info

Publication number
CY1107531T1
CY1107531T1 CY20071100343T CY071100343T CY1107531T1 CY 1107531 T1 CY1107531 T1 CY 1107531T1 CY 20071100343 T CY20071100343 T CY 20071100343T CY 071100343 T CY071100343 T CY 071100343T CY 1107531 T1 CY1107531 T1 CY 1107531T1
Authority
CY
Cyprus
Prior art keywords
analytes
treatment
protection
dry eye
eye disorders
Prior art date
Application number
CY20071100343T
Other languages
English (en)
Inventor
Peter G Klimko
Mark R Hellberg
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Publication of CY1107531T1 publication Critical patent/CY1107531T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Οι αναστολείς πρωτεασόμης είναι χρήσιμοι για την αγωγή διαταραχών ξηρού οφθαλμού και άλλων διαταραχών που απαιτούν την διαβροχή του οφθαλμού.
CY20071100343T 2001-05-21 2007-03-13 Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου CY1107531T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29272201P 2001-05-21 2001-05-21
EP02771849A EP1392355B1 (en) 2001-05-21 2002-05-17 Use of proteasome inhibitors to treat dry eye disorders

Publications (1)

Publication Number Publication Date
CY1107531T1 true CY1107531T1 (el) 2013-03-13

Family

ID=23125916

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100343T CY1107531T1 (el) 2001-05-21 2007-03-13 Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου

Country Status (17)

Country Link
US (1) US6740674B2 (el)
EP (1) EP1392355B1 (el)
JP (1) JP2004530699A (el)
CN (1) CN1509183A (el)
AT (1) ATE353667T1 (el)
AU (1) AU2002308760B2 (el)
BR (1) BR0209883A (el)
CA (1) CA2447909C (el)
CY (1) CY1107531T1 (el)
DE (1) DE60218153T2 (el)
DK (1) DK1392355T3 (el)
ES (1) ES2278049T3 (el)
MX (1) MXPA03010634A (el)
PL (1) PL367287A1 (el)
PT (1) PT1392355E (el)
WO (1) WO2002094311A1 (el)
ZA (1) ZA200308768B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
PL1948678T3 (pl) 2005-11-09 2013-09-30 Onyx Therapeutics Inc Związki do hamowania enzymów
EP2041158B1 (en) 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
PL2207791T5 (pl) * 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN103893742B (zh) * 2014-03-03 2016-01-20 中山大学中山眼科中心 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DE69115990T2 (de) 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
DK0643581T3 (da) 1992-04-21 2000-04-25 Schepens Eye Res Inst Okulær androgenbehandling ved Sjögren's syndrom
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
JPH1036289A (ja) 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
CA2281224A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
EP1017398A1 (en) 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
WO2000003705A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US6096733A (en) 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
WO2000043000A1 (fr) 1999-01-20 2000-07-27 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de proteasome
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
CA2370830C (en) 1999-04-27 2009-10-13 Novartis Ag Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors

Also Published As

Publication number Publication date
WO2002094311A1 (en) 2002-11-28
MXPA03010634A (es) 2004-03-09
BR0209883A (pt) 2004-06-08
ES2278049T3 (es) 2007-08-01
ZA200308768B (en) 2005-01-26
PL367287A1 (en) 2005-02-21
EP1392355A1 (en) 2004-03-03
PT1392355E (pt) 2007-03-30
US6740674B2 (en) 2004-05-25
EP1392355B1 (en) 2007-02-14
ATE353667T1 (de) 2007-03-15
AU2002308760B2 (en) 2006-05-11
JP2004530699A (ja) 2004-10-07
DE60218153T2 (de) 2007-06-28
US20030008910A1 (en) 2003-01-09
CN1509183A (zh) 2004-06-30
DE60218153D1 (de) 2007-03-29
CA2447909C (en) 2011-04-05
CA2447909A1 (en) 2002-11-28
DK1392355T3 (da) 2007-04-30

Similar Documents

Publication Publication Date Title
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
DE60114808D1 (de) Oberflächenbehandlung von medizinischer vorrichtung
DE60045386D1 (de) Gerät zur thermischen behandlung von bandscheiben
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
DE50214540D1 (de) Stanz bei der behandlung von wunden
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
ATE322898T1 (de) Inhibitoren von mycobakterien
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
TR200003084T2 (tr) Paroxetine askorbat
DK1393277T3 (da) Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
UA51054A (uk) Спосіб лікування післяінсультних порушень і пристрій для його реалізації
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento